Aquestive Therapeutics (AQST) Scheduled to Post Quarterly Earnings on Monday

Aquestive Therapeutics (NASDAQ:AQST) is scheduled to release its earnings data after the market closes on Monday, November 4th. Analysts expect Aquestive Therapeutics to post earnings of ($0.12) per share for the quarter. Aquestive Therapeutics has set its FY 2024 guidance at EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.08. The firm had revenue of $20.10 million for the quarter, compared to analyst estimates of $12.62 million. During the same period in the prior year, the business posted ($0.10) EPS. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aquestive Therapeutics Stock Up 0.5 %

Shares of NASDAQ:AQST opened at $5.52 on Friday. Aquestive Therapeutics has a 12-month low of $1.41 and a 12-month high of $6.23. The company’s 50 day moving average price is $4.86 and its two-hundred day moving average price is $3.80. The firm has a market cap of $502.65 million, a PE ratio of -15.77 and a beta of 2.85.

Wall Street Analysts Forecast Growth

AQST has been the topic of a number of analyst reports. Leerink Partners increased their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Friday, October 25th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $8.83.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.